Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models

[Image: see text] The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Chem Neurosci
Main Authors: Roy, Saktimayee M., Grum-Tokars, Valerie L., Schavocky, James P., Saeed, Faisal, Staniszewski, Agnieszka, Teich, Andrew F., Arancio, Ottavio, Bachstetter, Adam D., Webster, Scott J., Van Eldik, Linda J., Minasov, George, Anderson, Wayne F., Pelletier, Jeffrey C., Watterson, D. Martin
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2015
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4404319/
https://ncbi.nlm.nih.gov/pubmed/25676389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschemneuro.5b00002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados